Business News

four trending shares in healthcare to be careful for proper now

June
02/22/2021

Read 6 minutes

This story originally appeared on StockMarket

4 Top Healthcare Stocks To Put On Your Watchlist This Week

Health stocks were the focus of the stock market last year for obvious reasons. Everyone was amazed when we were plagued by the global pandemic. However, every crisis offers a new opportunity. Funding has been made available to the health industry more than ever as we are reminded of the importance of health. We are seeing many health stocks like Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) take the opportunity to fight the pandemic through their COVID-19 vaccines.

Moderna has made a name for itself by being one of the first companies in the world to receive the Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its coronavirus vaccine. Since then, the price of the MRNA share has increased more than tenfold. With this success, it comes as no surprise that many healthcare companies are constantly fighting for the next big breakthrough. After all, health care is something that we need at some point in our lives. Hence, we can understand why many investors are looking for top health stocks to invest in. If you are one of them, here are four names that are trending in the stock market today.

Top Healthcare Stocks You Should See Now

Cassava Sciences Inc

First, we have the clinical-stage biopharmaceutical company Cassava. The company focuses on the development of drugs to treat diseases of the nervous system. Cassava is currently the focus as it focuses on treating Alzheimer's disease. It does so after Biogen Inc (NASDAQ: BIIB) received accelerated FDA approval for its drug ADUHELM ™. So investors appear optimistic that Cassava's Simufilam and SavaDx could benefit from this development.

Simufilam is cassava's lead drug candidate for the treatment of Alzheimer's disease, while SavaDx is a diagnostic investigational candidate for the detection of Alzheimer's disease. The company will present its results from an interim safety and cognition analysis of the first 50 patients to complete 9 months of open-label drug treatment. These data will be presented at the Alzheimer's Association International Conference (AAIC) in Denver in 2021, scheduled for July 26-30. The company takes the opportunity to provide an update on its drug as it recognizes that clear evidence of the drug's effectiveness is essential.

In addition, Cassava also announced the selection of Premier Research International as its clinical research organization (CRO). Given that it has completed over 250 neuroscience clinical trials, the company believes Premier Research would be the ideal partner to bring simufilam into Phase 3 clinical trials. Do you think cassava can live up to its expectations? If so, would you consider buying SAVA stock?

Source: TD Ameritrade TOS

(Continue reading) 3 growth stocks that could be better investments right now than AMC stocks

BioNTech SE

BioNTech SE is a Germany-based biotechnology company in the clinical stage. The company is known for partnering with Pfizer for its COVID-19 vaccine. In addition, it focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The BNTX share has had an outstanding 2021 on the stock market so far. It has risen by over 160% since the beginning of the year.

Last week BioNTech announced that the first patient in its Phase 2 cancer vaccine study had been treated with BNT111. The study examines the combination of BNT111 with Libtayo® (cemiplimab) in patients with anti-PD1 refractory / relapsed unresectable melanoma stage III or IV. The company hopes to harness the power of the immune system against cancer and other infectious diseases. While the pandemic was the focus of the last year, we shouldn't forget that cancer is also a global health threat that requires attention.

Regarding his COVID-19 vaccine, he has received approval from the European Union to accept people aged 12-15. This follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on the approval of the vaccine in this age group. This is important as the provision of vaccines to adolescents will help reopen schools and help them return to normal everyday life. With all of these developments around the company, would you consider adding BNTX shares to your watchlist?

best health stocks (BNTX stock)Source: TD Ameritrade TOS

Continue reading

Vir Biotechnology Inc

Vir Biotechnology is a clinical stage immunology company focused on antibodies. Essentially, it focuses on developing treatments and prevention for serious infectious diseases. The pipeline consists of product candidates against hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). The VIR share has risen by over 80% since the beginning of the year.

On Monday, GlaxoSmithKline (NYSE: GSK) and Vir announced the final results of the COMET-ICE Phase 3 study (COVID-19 Monoclonal Antibody Efficacy Trial – Intent to Care Early). The study showed that sotrovimab significantly reduced the risk of hospitalization or death in high-risk outpatients with mild to moderate COVID-19. Fighting the pandemic isn't just about vaccinations, treating the infected is just as important, if not more important.

In addition, Vir announced last week that four of its abstracts highlighting data from its hepatitis B clinical program had been accepted for two oral and two poster presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress. So investors could expect some new positive data from its clinical program. With that in mind, would you keep an eye on VIR shares?

Buy Health Stocks Now (VIR Stock)Source: TD Ameritrade TOS

(Continue reading) Top Meme Stocks You Should See Today? 5 In focus

Natera Inc

To sum up the list, we have a pioneer and world leader in cell-free DNA testing, Natera. It deals with the discovery, development and commercialization of genetic testing. With its next generation cfDNA technology platform, it focuses on non-invasive blood-based testing in the areas of women's health, oncology and organ health. The NTRA share has been trading sideways since the beginning of the year. However, it shouldn't go unnoticed that he's picked up some speed and has gained over 25% in the last month.

Last Friday, Natera announced that the Centers for Medicare & Medicaid Services had granted Advanced Diagnostic Laboratory Test status for the Signatera Molecular Residual Disease (MRD) test. This means that Signatera meets the highly selective criteria of the Protecting Access to Medicare Act of 2014. Signatera is used for treatment monitoring and MRD assessment and can detect cancer recurrence up to two years before conventional imaging

In May, the company announced its earnings report for the first quarter. Natera had sales of $ 152.3 million, up 62% over the previous year. Product sales of this totaled $ 118.4 million. In addition, around 348,200 tests were processed in the first quarter of 2021, compared to 235,500 in the same quarter of the previous year. Given the current momentum, the company appears to be increasing its revenue forecast for the year by $ 50 million. All in all, would NTRA stock be one of the top healthcare stocks to buy?

The Best Health Stocks You Can Buy Right Now (NTRA Stock)Source: TD Ameritrade TOS

Related Articles